Erdheim–Chester disease
Erdheim–Chester disease (ECD) is a rare non-Langerhans cell histiocytosis characterized by the abnormal multiplication of histiocytes, a type of white blood cell. This disease was first described by the Austrian pathologist Jakob Erdheim and the American pathologist William Chester in 1930.
Presentation[edit | edit source]
ECD can affect multiple organ systems, leading to a wide range of symptoms. Commonly affected areas include the long bones, cardiovascular system, central nervous system, kidneys, and retroperitoneum. Patients may present with bone pain, diabetes insipidus, neurological deficits, and cardiovascular symptoms such as pericardial effusion.
Pathophysiology[edit | edit source]
The exact cause of ECD is unknown, but it is believed to involve a clonal proliferation of histiocytes. These cells infiltrate various tissues and organs, leading to fibrosis and organ dysfunction. Mutations in the BRAF gene, particularly the BRAF V600E mutation, have been identified in a significant number of ECD cases.
Diagnosis[edit | edit source]
Diagnosis of ECD is challenging due to its rarity and the variability of its symptoms. It often requires a combination of imaging studies, biopsy of affected tissues, and genetic testing for mutations such as BRAF V600E. X-ray and MRI are commonly used to identify characteristic bone lesions, while CT scan and PET scan can help assess the extent of organ involvement.
Treatment[edit | edit source]
There is no standard treatment for ECD, and management often involves a multidisciplinary approach. Treatment options may include:
- Interferon-alpha
- Targeted therapy with BRAF inhibitors (e.g., vemurafenib)
- Chemotherapy
- Radiation therapy
- Corticosteroids
Prognosis[edit | edit source]
The prognosis for ECD varies widely depending on the extent of organ involvement and response to treatment. Some patients may experience a chronic course with relatively stable disease, while others may have a more aggressive progression.
Related Pages[edit | edit source]
Categories[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD